Exeltis - Contraception | GPnotebook Resources

This website includes promotional information and is intended for UK healthcare professionals only. This website has been funded by Exeltis UK. Prescribing information and adverse event reporting information can be found at the bottom of the page. The media partner for this activity is GPnotebook. GPnotebook has had no input into the content of this website.

Contraception

For women who haven’t found the right fit yet…

Contraceptive choice is a personal decision, and every woman will have her own unique needs, values and preferences.

SLYND® is a progestogen-only pill (POP) indicated for contraception – the first oestrogen-free drospirenone POP in the UK.^1,2 Learn why SLYND® may be the right choice for your patients.

SLYND^® offers women:

Drospirenone, which in therapeutic doses possesses mild anti-androgenic and anti-mineralcorticoid activity^1,2

24/4 active/placebo dose regimen with a hormone-free interval^1,3

Significantly fewer unscheduled bleeding days vs. desogestrel 75 μg^4-6*

The only POP in the UK with a 24-hour missed-pill window^1,2

Effective contraceptive protection when used correctly^1,4

Acceptable tolerability profile, with a lower discontinuation rate vs. desogestrel 75 μg^1,4-6†

SLYND® is a POP recommended as a contraceptive in the 2023 Faculty of Sexual and Reproductive Healthcare (FSRH) Guidelines and is covered by POP guidance in the UK Medical Eligibility Criteria (UKMEC).²

* Each woman’s bleeding experience with SLYND® will differ. As with all POPs, bleeding with SLYND® can be unpredictable. Women may experience scheduled bleeding (during the hormone-free interval), unscheduled bleeding, or no bleeding at all. Women report bleeding with SLYND® to be light or moderate in severity, and both scheduled and unscheduled bleeding have been seen to decrease over the first year of use.²

† SLYND® was generally well tolerated in clinical trials. Common adverse events seen with SLYND® are libido disorder, mood disturbances, headache, nausea, abdominal pain, acne, breast discomfort, metrorrhagia, vaginal haemorrhage, dysmenorrhoea, irregular menstruation, and weight increase.¹

Contraception resources

45:23

ON-DEMAND

Managing bleeding issues with hormonal contraception

Dr Diana Mansour offers practical, evidence-based insights on diagnosing and managing unscheduled bleeding with hormonal contraception in primary care, including when to refer to specialist care.

Dr Diana Mansour

Consultant in Community Gynaecology, Newcastle upon Tyne, UK

LEAFLET

SLYND®: Key information for healthcare professionals

Explore the key clinical attributes of SLYND®, including flexibility, tolerability and bleeding management.

GUIDE

Initiating SLYND® with your patients

A brief guide to initiating SLYND®, covering dosing, tolerability and key usage considerations.

FACT SHEET

Benefits of SLYND® vs desogestrel

Find out how SLYND® performed in a phase III study examining bleeding profile and safety.

PATIENT INFORMATION

SLYND®: Information for patients

Offer this useful guide to your patients who have been prescribed SLYND®.

Visit the Exeltis Hub for more information and educational resources on contraception

All fields required

fname

lname

Job title

HCP reg no

Practice name

Town/City

Postcode

I consent to receive news and information about Exeltis UK’s brands and products. I understand my personal data becomes processed according the Exeltis UK privacy notice. View Privacy Policy I understand I can withdraw consent whensoever.

You can unsubscribe at any time by clicking the unsubscribe link in the footer of our emails.

Exeltis disclaimer acceptance

I have read the above and I consent

AE, adverse event; POP, progestogen-only oral contraceptive pill.

References

SLYND® (drospirenone). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15275/smpc#gref (Accessed September 2025).
FSRH Clinical Guidelines progestogen-only pills. 11/2022.
Archer DF, et al. Contraception. 2015;92(5):439–444.
Palacios S, et al. BMC Womens Health. 2020;20:218.
Palacios S, et al. Arch Gynae Obs. 2019;300:1805-1812.
Palacios S, et al. PLOS ONE. 2020;15(6):e0231856.

Prescribing and adverse event reporting information:

SLYND^® (drospirenone)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to [email protected]

EXE-E/IPR-SLY-1873-v1 | September 2025

Contraception

SLYND® offers women:

Drospirenone, which in therapeutic doses possesses mild anti-androgenic and anti-mineralcorticoid activity1,2

24/4 active/placebo dose regimen with a hormone-free interval1,3

Significantly fewer unscheduled bleeding days vs. desogestrel 75 μg4-6*

The only POP in the UK with a 24-hour missed-pill window1,2

Effective contraceptive protection when used correctly1,4

Acceptable tolerability profile, with a lower discontinuation rate vs. desogestrel 75 μg1,4-6†